Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,669

Document Document Title
WO/2018/163194A1
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.  
WO/2018/159964A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to pro...  
WO/2018/155340A1
The purpose of the present invention is to provide a liquid crystalline compound; a liquid crystal composition containing the compound; and a liquid crystal display element including the composition, the liquid crystalline compound satis...  
WO/2018/154493A1
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2018/149857A1
The present invention relates to novel 2-oxo-2H-chromen compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositio...  
WO/2018/150421A1
The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).  
WO/2018/149991A1
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...  
WO/2018/146471A1
There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings5 provided in the description, which compounds are useful in the treatment of cancers.  
WO/2018/141706A1
The invention relates to propellane compounds according to defined formula, to the use of said compounds in electronic devices, and to electronic devices containing one or more of the known propellane compounds. The invention also relate...  
WO/2018/138029A1
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate...  
WO/2018/139767A1
The present invention provides a novel amine-based compound and an organic light emitting device using the same.  
WO/2018/133795A1
An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat ...  
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/122232A1
Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.  
WO/2018/116185A1
The invention discloses compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, A, R19, R20, and R21 are as defined herein. The present invention relates to deuterated compounds and their ...  
WO/2018/113201A1
A compound as represented by formula (I), or a stereoisomer, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof, a preparation method therefor, a pharmaceutical composition comprising ...  
WO/2018/112331A1
The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segm...  
WO/2018/104295A1
Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases...  
WO/2018/099431A1
Disclosed is a pyrene organic compound having the following structural formula. The pyrene organic compound has better charge transfer performance and luminous efficiency, and also has better thermal stability. Therefore, by providing an...  
WO/2018/100834A1
Provided is a composition that has excellent near-infrared ray absorption stability and is useful for an optical film. The composition includes at least two of the compounds represented by general formula 2 or general formula 5.  
WO/2018/098831A1
Provided are a biomass-based epoxy resin and method for preparation thereof; under conditions of N,N-dimethylformamide as a catalyst, 2,5-furandicarboxylic acid and thionyl chloride are acylated to obtain 2,5-furan diformyl chloride; the...  
WO/2018/089330A2
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/089330A3
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...  
WO/2018/089406A1
There are described RORɣ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical composi...  
WO/2018/084266A1
Herein disclosed are compounds, compositions, kits, and methods of treating cancers using 7-azaindolyl furanone/thiophene derivatives. These derivatives inhibit serine-threonine kinase Cdc7, a recognized anticancer target affecting DNA r...  
WO/2018/078005A1
The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful...  
WO/2018/067382A1
Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially ...  
WO/2018/064119A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2018/062778A1
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...  
WO/2018/062984A3
The present invention relates to an improved method for the synthesis of dendron-based chromatography resins. The method comprises incorporating dendrons, molecules having a branched structure, into the chromatography resin. In a second ...  
WO/2018/055402A1
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...  
WO/2018/053588A1
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.  
WO/2018/057973A4
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...  
WO/2018/054989A1
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...  
WO/2018/057973A1
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...  
WO/2018/054989A4
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...  
WO/2018/054989A9
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...  
WO/2018/050477A1
The present invention relates to relates to novel strigolactone derivatives of formula (I), to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, to plant growth regulator o...  
WO/2018/033088A1
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...  
WO/2018/033085A1
Disclosed are a compound using anthrone as a core and applications thereof in an organic electroluminescent component. The compound uses anthrone as a parent core, which is connected to an aromatic heterocyclic group, so that the molecul...  
WO/2018/031877A1
Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to...  
WO/2018/024017A1
The present invention relates to a preparation method for 6-fluoro-2-(epoxy-2-yl)chroman. The preparation method comprises the following steps: (1) if a compound as represented by formula (II) is in an R form, subjecting a compound as re...  
WO/2018/024907A1
The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward cancer cell cultures and, more particularly, PANC-1 cancer cell cultures than FK866. Accordingly, the present invention ...  
WO/2018/021890A1
The present invention relates to a novel cromenone derivative compound having heat shock protein 27 (HSP27) inhibitory activity. The composition, a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the s...  
WO/2018/015292A1
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cance...  
WO/2018/016615A1
Provided is a compound represented by formula (0). (0) (RY is a C1–30 alkyl group or a C6–30 aryl group; RZ is a C1–60 N-valent group or a single bond; and RT is a C1–30 alkyl group, a C6–30 aryl group, a C2–30 alkenyl group,...  
WO/2018/004202A1
The present invention relates to an improved method for producing a diphenylmethane derivative useful as a sodium-dependent glucose cotransporter (SGLT) inhibitor. Performed in a convergent synthesis manner in which main groups are indiv...  
WO/2018/002948A1
In accordance with the present subject matter there is provided sugar-based compounds of formula I, methods of making such compounds, gels comprising such compounds, methods of making gels, methods of using such compounds for the contain...  
WO/2017/220446A1
The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benz oic acid (referred to herein as "BHBA-001"), which...  

Matches 1 - 50 out of 6,669